New malaria vaccine for pregnant women passes first safety test
NCT ID NCT02658253
First seen Dec 08, 2025 · Last updated Apr 28, 2026 · Updated 27 times
Summary
This early-stage trial tested a vaccine called PRIMVAC, designed to protect pregnant women from malaria. Researchers gave three different doses to 68 healthy adults in France and Burkina Faso to check for safety and immune response. The vaccine uses two different adjuvants (Alhydrogel or GLA-SE) to boost effectiveness. Results will guide further development of a vaccine to prevent dangerous malaria infections during pregnancy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CIC 1417
Paris, 75679, France
-
CNRFP
Ouagadougou, BP 2208, Burkina Faso
Conditions
Explore the condition pages connected to this study.